Drug Profile
Neladenoson bialanate - Bayer HealthCare Pharmaceuticals
Alternative Names: BAY 1067197Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Bayer HealthCare Pharmaceuticals
- Class Heart failure therapies; Nitriles; Pyridines; Pyrrolidines; Thiazoles
- Mechanism of Action Adenosine A1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Chronic heart failure
Most Recent Events
- 01 Apr 2020 Discontinued - Phase-II for Chronic heart failure in Portugal, Japan, Israel, Greece, Belgium, USA, Austria, Bulgaria, Spain, Poland, Italy, Germany, Netherlands (PO) (NCT04322253)
- 25 Mar 2020 Bayer terminated a phase I trial due to cessation of development project for Neladenoson bialanate in Germany (NCT04322253)
- 20 Jun 2018 Bayer completes a phase II trial in Chronic heart failure in USA, Austria, Germany, Bulgaria, Spain, Portugal, Greece, Belgium, Israel, Italy, Japan and Poland (PO) (NCT03098979)